EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Advances in Multimodality Management of Localized Non-Small Cell Lung Cancer

Sushma Jonna, Jowan Al Nusair, Giordano Fabricio Cittolin Santos, Shadia Jalal

Seminars in Respiratory and Critical Care Medicine · 01.10.2025 · 46 (05) · 520-529

DOI: 10.1055/a-2715-6723 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Seminars in Respiratory and Critical Care Medicine, erschienen am 01.10.2025. Verfasst von Sushma Jonna und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Oncology, Durham Veterans Affairs Hospital, Durham, North Carolina. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit nennt 61 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lung cancer represents the most common cause of cancer-related mortality globally, with non-small cell lung cancer (NSCLC) comprising the vast majority of cases. Outcomes for stage II–III NSCLC remain suboptimal due to late presentation, biological heterogeneity, and limited efficacy of traditional therapies. Recent advances have reshaped the therapeutic landscape, with immunotherapy and targeted treatments now integrated into the management of resectable NSCLC. Landmark trials such as CheckMate 816 demonstrated improved event-free and overall survival with neoadjuvant chemoimmunotherapy approaches. Similarly, adjuvant targeted therapies such as osimertinib and alectinib have shown benefit in patients with EGFR and ALK alterations, respectively. This review provides an overview of evolving diagnostic strategies, highlights pivotal clinical trials, and explores multidisciplinary treatment approaches across stages I to III NSCLC. We also address key challenges including optimal treatment sequencing, patient selection, and duration of therapy. As clinical trial data continue to mature, personalized multimodal strategies guided by molecular and clinical features remain central to improving long-term outcomes in resectable NSCLC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsHumansCombined Modality TherapyNeoplasm StagingImmunotherapyNeoadjuvant TherapyMolecular Targeted Therapy

Autor:innen und Institutionen

  • Division of Oncology, Durham Veterans Affairs Hospital, Durham, North Carolina.
  • Department of Internal Medicine, Marshall University, Huntington, West Virginia.
  • Division of Oncology, Washington University in St. Louis School of Medicine, St. Louis, Missouri.
  • Division of Oncology, John Cochran VA Medical Center, St. Louis, Missouri.
  • Devision of Oncology, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana.

Zitieren

APA

Jonna, S., Nusair, J. A., Santos, G. F. C., & Jalal, S. (2025). Advances in Multimodality Management of Localized Non-Small Cell Lung Cancer. Seminars in Respiratory and Critical Care Medicine, 46(05), 520-529. https://doi.org/10.1055/a-2715-6723

Vancouver

Jonna S, Nusair JA, Santos GFC, Jalal S. Advances in Multimodality Management of Localized Non-Small Cell Lung Cancer. Seminars in Respiratory and Critical Care Medicine. 2025;46(05):520-529. doi:10.1055/a-2715-6723

BibTeX
@article{Jonna2025,
  author = {Jonna, Sushma and Nusair, Jowan Al and Santos, Giordano Fabricio Cittolin and Jalal, Shadia},
  title = {Advances in Multimodality Management of Localized Non-Small Cell Lung Cancer},
  journal = {Seminars in Respiratory and Critical Care Medicine},
  year = {2025},
  volume = {46},
  number = {05},
  pages = {520--529},
  doi = {10.1055/a-2715-6723}
}
Kostenlos starten →